FIGURE

Fig. 5

ID

ZDB-FIG-221114-19

Publication

Harms et al., 2021 - An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

Competition of EPI-X4, WSC02, JM#21 and AMD3100 with the CXCR4 ECL-2 antibody 12G5. CXCR4 expressing SupT1 cells were precooled and assay buffer was removed. EPI-X4 and the optimized derivatives WSC02 and JM#21, and the small molecule AMD3100 were diluted in cold PBS and added to the cells. Immediately afterwards, a constant concentration of the APC-labelled CXCR4 antibody (clone 12G5) was added. After 2 h incubation at 4 °C unbound antibody was removed and cells analyzed in flow cytometry. Data were represented as mean ± SEM (n = 3). IC₅₀ values were calculated by non-linear regression.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Acta Pharm Sin B